GLP-1 Market Size, Share
US$ 27.20
noom oral semaglutide jumps into off-brand weight loss drug market Microdosing GLP-1 for Weight Loss
Description
This addressed potential biases due to decreased health care utilization from the COVID-19 pandemic, and the 60% increased prescription of semaglutide from 2021 to 2023 after FDA approval for obesity
2017 Nov;174(11):1325-1348
Result: actual belly fat loss
Phase 2 trial data showed no plateau at the 48-week endpoint
Cost, insurance coverage, and availability can vary between commercial and compounded products
Determining the Right GLP-1 Dosage for Weight Loss Deciding the correct dosage of GLP-1 is crucial for maximizing weight loss results while minimizing side effects
